Ariadne's ChemEffect and Pathway Studio knowledge base

Expert Opinion on Drug Discovery

Volumn 4, Issue 12, 2009, Pages 1307-1318

  Yuryev, Anton ^a   Kotelnikova, Ekaterina ^a   Daraselia, Nikolai ^a  

^a NONE   (United States)

Author keywords

Cholestasis; Glioblastoma; Information extraction; MedScan; Natural language processing; Systems biology

Indexed keywords

BIOLOGICAL MARKER; CHLORPROMAZINE; CIMETIDINE; CLARITHROMYCIN; CLOZAPINE; COLCHICINE; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; EZETIMIBE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; FULVESTRANT; GLIBENCLAMIDE; HYDROCORTISONE; METHYLPREDNISOLONE; OSTEOCLAST DIFFERENTIATION FACTOR; RANITIDINE; SILIBININ; TACROLIMUS; TRABECTEDIN; TROGLITAZONE; TUMOR NECROSIS FACTOR; VASCULOTROPIN A;

ALGORITHM; CHEMEFFECT; CHOLESTASIS; COMPUTER PROGRAM; DATA MINING; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; INFORMATION TECHNOLOGY; KNOWLEDGE BASE; METABOLOMICS; NATURAL LANGUAGE PROCESSING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SCIENTIFIC LITERATURE;

EID: 73549106803     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903413488     Document Type: Review

References (50)

1. Novichkova S, Egorov S, Daraselia N. MedScan, a natural language processing engine for MEDLINE abstracts. Bioinformatics 2003;19(13):1699-1706
2. Sivachenko A, Yuryev A. Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. Expert Opin Ther Targets 2007;11(3):411-421
3. Daraselia N, Yuryev A, Egorov S, et al. Automatic extraction of gene ontology annotation and its correlation with clusters in protein networks. BMC Bioinformatics 2007;8(1):243
4. Blaschke C, Leon EA, Krallinger M, Valencia A. Evaluation of BioCreAtIvE assessment of task 2. BMC Bioinformatics 2005;6(Suppl 1):S16
5. Available from: http://www.drugbank.ca
6. Available from: http://matadorembl.de
7. Available from: http://insilico.charite.de/ supertarget
8. Available from: http://bidd.nus.edu.sg/ group/cjttd/TTD-ns.asp
9. Available from: http://pubchem.ncbi.nlm. nih.gov
10. Available from: http://chembank.broad. harvard.edu
11. Available from: http://sideeffects.embl.de/
12. Available from: http://www.accessdata.fda. gov/Scripts/cder/DrugsatFDA
13. http://clinicaltrials.gov
14. Available from: http://www.genego.com/ metadrug.php
15. Available from: http://www.ingenuity. com/products/ipa-tox.html
16. Available from: http://www.camcellnet. com
17. Available from: http://www.gvkbio.com/ informatics.html
18. Sivachenko AY, Yuryev A, Daraselia N, Mazo I. Molecular networks in microarray analysis. J Bioinform Comput Biol 2007;5(2B):429-456
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102(43):15545-15550
20. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-77
21. Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000;9:1383-1396
22. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002;2:564-573 (Pubitemid 34966359)
23. Fang J, Chen SJ, Tong JH, et al. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biol Ther 2002;1:614-620
24. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448(7154):645-646
25. Wong ML, Kaye AH, Hovens CM. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 2007;21:301-308
26. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit Rev Oncol Hematol 2006;59(3):181-193
27. Ziegler DS, Wright RD, Kesari S, et al. Resistance of human glioblastoma multiform cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008;118(9):3109-3122
28. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170(5):1445-1453
29. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005;25(1):1-7
30. Mueller W, Nutt CL, Ehrich M, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007;26(4):583-593
31. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004;64:1987-1996
32. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355-6360
33. Jin Y, Kim HP, Ifedigbo E, et al. Cyr61 protects against hyperoxia-induced cell death via Akt pathway in pulmonary epithelial cells. Am J Respir Cell Mol Biol 2005;33(3):297-302
34. Kunz M, Moeller S, Koczan D, et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 2003;278(46):45651-45660
35. Tsai MS, Bogart DF, Li P, et al. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 2002;21(6):964-973
36. Yen ML, Su JL, Chien CL, et al. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. Mol Pharmacol 2005;68(4):1061-1073
37. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183
38. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494
39. Wang R, Zhang QG, Han D, et al. Inhibition of MLK3-MKK4/7-JNK1/2 pathway by Akt1 in exogenous estrogen-induced neuroprotection against transient global cerebral ischemia by a non-genomic mechanism in male rats. J Neurochem 2006;99(6):1543-1554
40. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 2006;17(2):200-204, [Epub 26 October 2005]
41. Schneider SW, Ludwig T, Tatenhorst L, et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 2004;107(3):272-276, [Epub 17 January 2004]
42. Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 2007;46(3):365-371
43. Miyata M, Tozawa A, Otsuka H, et al. Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity. J Pharmacol Exp Ther 2005;312(2):759-766
44. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002;23(5):687-702
45. Zollner G, Wagner M, Moustafa T, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006;290(5):G923-32
46. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005;115(1):177-186
47. Martínez-Jiménez CP, Gómez-Lechón MJ, Castell JV, Jover R. Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/ enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 2005;67(6):2088-2101
48. Jigorel E, Le Vee M, Boursier-Neyret C, et al. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006;34(10):1756-1763
49. Staudinger JL, Madan A, Carol KM, Parkinson A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 2003;31(5):523-527
50. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009;49(1):297-305